Doxacurium | 133814-18-3

• 物质功能分类: 原料药 - 影响组织代谢的药物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: Doxacurium
• 英文别名: bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
• CAS: 133814-18-3
• 化学式: C56H78N2O16+2
• 分子量: 1035.2
• InChiKey: GBLRQXKSCRCLBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  74
• 可旋转键数：
  29
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  163
• 氢给体数：
  0
• 氢受体数：
  16

ADMET

代谢

活体人体数据显示，氯唑库铵不发生代谢，主要的消除途径是药物原形通过尿液和胆汁排出。

In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.

来源:DrugBank

毒理性

• 蛋白质结合

大约30%。

Approximately 30%.

来源:DrugBank

吸收、分配和排泄

• 消除途径

人体内的数据表明，NUROMAX不被代谢，主要的消除途径是药物以原形在尿液和胆汁中排出。

In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.

来源:DrugBank

吸收、分配和排泄

• 分布容积

0.11-0.43 升/千克 [健康成年患者] 0.17-0.55 升/千克 [肾脏移植患者] 0.17-0.35 升/千克 [肝脏移植患者]

0.11-0.43 L/kg [Healthy Young Adult Patients] 0.17-0.55 L/kg [Kidney Transplant Patients] 0.17-0.35 L/kg [Liver Transplant Patients]

来源:DrugBank

吸收、分配和排泄

• 清除

2.66 mL/min/kg [健康的年轻成年患者] 1.23 mL/min/kg [肾脏移植患者] 2.3 mL/min/kg [肝脏移植患者] 1.75 +/- 0.16 mL/min/kg [老年患者（70-83岁）] 2.54 +/- 0.24 mL/min/kg [年轻患者（19-39岁）]

2.66 mL/min/kg [Healthy Young Adult Patients] 1.23 mL/min/kg [Kidney Transplant Patients] 2.3 mL/min/kg [Liver Transplant Patients] 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)] 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]

来源:DrugBank

文献信息

• [EN] REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE<br/>[FR] AGENTS DE BLOCAGE NEUROMUSCULAIRES NON DÉPOLARISANTS RÉVERSIBLES ET LEUR MÉTHODE
  申请人：UNIV CORNELL

  公开号：WO2010107488A1

  公开（公告）日：2010-09-23

  The invention provides neuromuscular blockade agents of the non-depolarizing type with few if any circulatory effects. Compounds of the invention include bis(isoquinolylalkanol) diesters of fumaric, maleic, succinic, and acetylenedicarboxylic acids; compositions suitable for parenteral administration of these compounds as a surgical adjunct to anesthesia, and methods of preparation of the compounds. Compounds of the invention can produce neuromuscular blockade of short or intermediate duration, which for various compounds can be reversed by administration of a thiol compound such as L-cysteine, D-cysteine or glutathione. For various compounds of the invention, the neuromuscular blockade effect can be reversed quickly, efficiently, and without notable side-effects.

  该发明提供了一种非去极化型神经肌肉阻滞剂，几乎没有任何循环效应。该发明的化合物包括富马酸、马来酸、琥珀酸和乙炔二羧酸的双(异喹啉基烷醇)二酯；适用于这些化合物作为手术辅助麻醉剂的静脉给药组合物，以及这些化合物的制备方法。该发明的化合物可以产生短暂或中等持续时间的神经肌肉阻滞，对于各种化合物，可以通过给予硫醇化合物如L-半胱氨酸、D-半胱氨酸或谷胱甘肽来逆转。对于该发明的各种化合物，神经肌肉阻滞效应可以迅速、高效地逆转，而且没有明显的副作用。
• REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE
  申请人：Savarese John J.

  公开号：US20120095041A1

  公开（公告）日：2012-04-19

  The invention provides neuromuscular blockade agents of the non-depolarizing type with few if any circulatory effects. Compounds of the invention include bis(isoquinolylalkanol) diesters of fumaric, maleic, succinic, and acetylenedicarboxylic acids; compositions suitable for parenteral administration of these compounds as a surgical adjunct to anesthesia, and methods of preparation of the compounds. Compounds of the invention can produce neuromuscular blockade of short or intermediate duration, which for various compounds can be reversed by administration of a thiol compound such as L-cysteine, D-cysteine or glutathione. For various compounds of the invention, the neuromuscular blockade effect can be reversed quickly, efficiently, and without notable side-effects.

  本发明提供了一种非去极化型的神经肌肉阻滞剂，其循环效应很少或没有。该发明的化合物包括富马酸、马来酸、琥珀酸和乙炔二羧酸的双(异喹啉基烷醇)二酯；适用于这些化合物的静脉注射制剂作为麻醉手术辅助剂，以及制备这些化合物的方法。该发明的化合物可以产生短期或中等期的神经肌肉阻滞效果，对于各种化合物，可以通过给予巯基化合物如L-半胱氨酸、D-半胱氨酸或谷胱甘肽来逆转。对于该发明的各种化合物，神经肌肉阻滞效果可以快速、有效地逆转，且没有明显的副作用。
• ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS
  申请人：UNIVERSITY OF MARYLAND, COLLEGE PARK

  公开号：US20170246180A1

  公开（公告）日：2017-08-31

  Provided are methods for reversing the effects of drugs of abuse. The method involves administering acyclic CB[n]-type compounds to a mammal in need of the reversal of the effects from a drug of abuse.
• US9469648B2
  申请人：——

  公开号：US9469648B2

  公开（公告）日：2016-10-18
• US9956229B2
  申请人：——

  公开号：US9956229B2

  公开（公告）日：2018-05-01